No news, no interest, no volume.
But ... RWC super results will be announced soon and the FDA will prompt Celsion to filed for the approval and make the treatment available as the new method of treatment for recurrent chest wall cancer.
Then, overnight, everything changed. The share price will rise to $ 50
Another method of operation. CYTR
The widely used chemotherapeutic agent doxorubicin is delivered systemically and is highly toxic, which limits its dose to a level below its maximum therapeutic benefit. Doxorubicin also is associated with many side effects, especially the potential for damage to heart muscle at cumulative doses greater than 450 mg/m2. Aldoxorubicin combines doxorubicin with a novel single-molecule linker that binds directly and specifically to circulating albumin, the most plentiful protein in the bloodstream. Protein-hungry tumors concentrate albumin, thus increasing the delivery of the linker molecule with the attached doxorubicin to tumor sites. In the acidic environment of the tumor, but not the neutral environment of healthy tissues, doxorubicin is released. This allows for greater doses (3 ½ to 4 times) of doxorubicin to be administered while reducing its toxic side effects. In studies thus far there has been no evidence of clinically significant effects of aldoxorubicin on heart muscle, even at cumulative doses of drug well in excess of 2,000 mg/m2.
and of course out comes another of its imposter aliases....which one you going to use next? I don't think I've ever "bashed" clsn, maybe mgt once in awhile, but the old posters don't post because until something positive happens there isn't much to say, imho...
bwatson posts factual information, not BS, and all you two can do is bash. Obviously the noise of which he speaks. It's no wonder the old-timers continue to avoid this message board.
Gravy, that is not the original BW, this one is the immature imposter that created multiple fake ids of a lot of the old posters including me. If by chance I'm wrong BW has my non-yahoo email and he can send me a note and I'll stand corrected.
Before this system will be suitable for commercial use, will pass 5 years or more.. So there is no fear.
thanks for the heads up....I'll surely make my investment decision from info posted by a complete #$%$ on yahoo....just sayin
Bio-inspired 'nano-cocoons' offer targeted drug delivery against cancer cells
Raleigh, NC | Posted on October 14th, 2014
Biomedical engineering researchers have developed a drug delivery system consisting of nanoscale "cocoons" made of DNA that target cancer cells and trick the cells into absorbing the cocoon before unleashing anticancer drugs. The work was done by researchers at North Carolina State University and the University of North Carolina at Chapel Hill.
Sentiment: Strong Sell
A new paper just published by Dr Zhen Gu from North Carolina State University showing new NANO-COCOON technology pretty much makes this Themodox old news Google it. not bashing just be aware
You are absolutely correct -- this has always been the case and I see it is getting worse.
I lost money on this company in the past -- and check back from time to time. It amazes me that Tardungo's comp is over $800K with the small operation that it has. That is just disgraceful -- particularly given the failures in performance. There is no one to blame but the Board -- asleep at the wheel, or part of the scam?
Personal opinions about buyouts and derogatory comments of management is just noise.
Future data is what matters.
I predict a pop on the next RCW data. And I don't think there will be a phase 3 RCW study.
There's already quite a bit of safety and efficacy data (single tumor HCC) from the HEAT study.
Perhaps the FDA will recommend a new drug application for RCW.